386 results about "Kinase protein" patented technology

Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.

The invention relates to application of mitogen-activated protein kinase PiPmk1 in screening molecules for inhibiting formation of a phytophthora infestans infection structure. The invention finds that the molecular marker plays a key role in the development of a phytophthora infestans cyst bud tube and / or the formation of an infection structure, which indicates that the molecular marker has the potential of serving as a target for inhibiting phytophthora infestans infection, and a corresponding molecular screening method and a generative prediction model are further developed and utilized; rapid and accurate prediction and screening of phytophthora infestans infection inhibitory molecules are realized, the research and development period and cost are greatly shortened, and a new thought and a new method are provided for development of accurate targeted green pesticides.

The invention belongs to the field of plant genetic engineering, and discloses a key gene OsHPCA1 for positively regulating salt stress and oxidative stress tolerance of rice. The gene (with the login number of Os05g40770) encodes a receptor protein capable of specifically sensing hydrogen peroxide, and belongs to a leucine repeat receptor-like protein kinase (LRR-RLKs) family, wherein the family is the largest subfamily in the receptor-like protein kinase (RLKs). The OsHPCA1 responds to salt and oxidative stress signals, and the salt tolerance and oxidative stress resistance of the rice are positively regulated and responded. The OsHPCA1 overexpression rice strain shows very strong salt tolerance; and the OsHPCA1 knockout strain oshpca1 is more sensitive to salt stress. The OsHPCA1 protein encoded by the OsHPCA1 gene and rich in leucine repeat receptor-like protein kinase can positively regulate and control the activity of catalase C (CatC) in rice and enhance the removal efficiency of H2O2 under salt stress, so that the salt tolerance of rice is improved. When the OsHPCA1 is overexpressed, the activity of CatC in the overexpressed strain OsHPCA1 is obviously increased, the H2O2 removal capability is enhanced, and the salt tolerance and oxidative stress tolerance of the rice are improved.

The present invention relates to compounds of formula (I) below, or any one of its pharmaceutically acceptable salts: [Formula 1] JPEG2023523788000127.jpg41170 where R 1 is (C1-C6) alkyl group, spiro (C5-C 11 ) bicyclic rings, fused phenyl groups, substituted phenyl groups, R'-L- groups, where L is either a single bond or a (C1-C3) alkanediyl group, and R' is a (C3-C8) cycloalkyl group, a bridged (C6-C 10 ) cycloalkyl group, (C3-C8) heterocycloalkyl group, or (C3-C8) heteroaryl group, or R'-L- group, where L is a (C1-C3) alkanediyl group and R' is an optionally substituted phenyl group, and R 2 represents a hydrogen atom or a (C1-C3) alkyl group. The present invention further relates to compositions comprising the compound of formula (I), as well as methods for preparing the compound and synthetic intermediates thereof. The present invention also relates to the compound for use as a pharmaceutical, in particular for treating and / or preventing cognitive impairment associated with Down's syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 deficiency disorders; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; folate and methionine metabolism disorders; osteoarthritis; Duchenne muscular dystrophy; some cancers; neuroinflammation, anemia, and viral and unicellular infections, and for regulating body temperature.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.

The invention belongs to the technical field of plant genetic engineering, and particularly discloses application of an important member of a potato mitogen-activated protein kinase (MAPK) family, namely an StMKK9 gene in regulation and control of maturity and cold resistance of potatoes. CDNA of a cultivar Desiree leaf is used as a template, the potato StMKK9 gene is separated and cloned, an over-expression vector is constructed, and the over-expression vector is used for expression of the potato. Genetic transformation of the potatoes is further carried out, it is found that the overexpressed StMKK9 gene can promote prematurity of the potatoes, meanwhile, the cold resistance of potato plants can be improved, and a new genetic material and a theoretical basis are provided for analysis of a potato tuberization molecular mechanism and improved breeding of the potatoes.

The application relates to the field of agricultural disease control technology, and particularly relates to the use of indole compounds and pharmaceutically acceptable salts, solvates, crystal forms, prodrugs, stereoisomers and tautomers thereof for preparing a medicine for inhibiting pathogenic key protein kinase CgSlt2 of pathogenic fungi. The application first proposes a new type of CgSlt2-targeted inhibitor, specifically, indole compounds ((S)-N-(1-(1H-indol-3-yl)-4-(methylamino)-4-oxobutan-2-yl)-8-bromo-1,6-naphthyridine-2-carboxamide) and ((S)-N-(2-((1H-indol-3-yl)-1-(methylamino)-1-oxopropyl)-8-bromo-1,6-naphthyridine-2-carboxamide) are used as CgSlt2 inhibitors, have the characteristics of high target specificity and high activity, and exhibit excellent pathogenicity inhibition of a strain of the complex group of Colletotrichum gloeosporioides.

Developed and provided is a method for creating an area-restricted search type arthropod which belongs to the class Insecta or Arachnida and has high selection efficiency.　An area-restricted search type arthropod having high selection efficiency is created by measuring the expression level of a cGMP-dependent protein kinase gene in each test individual in a homogeneous individual group and selecting a test individual of which the expression level is significantly higher than that of a wild-type control individual.

The present invention relates to an aryl substituent-containing degradation agent for cyclin-dependent kinase 12 / 13 (CDK12 / 13), a preparation method therefor, and a pharmaceutical composition and use thereof. The degradation agent for CDK12 / 13 of the present invention has a structure represented by formula (I). The compound can be used as a protein kinase degradation agent, and can effectively and highly selectively degrade a CDK12 / 13 protein and inhibit proliferation, migration, and invasion of various tumor cells.

This invention discloses compounds of Formula I, or pharmaceutically acceptable salts, isomers, racemates, precursors, or solvates thereof. Compounds of Formula I exhibit excellent inhibitory activity against RSK protein kinase, thus showing promise for development into drugs targeting RSK.

The present disclosure relates to methods of treating solid tumors by administering a therapeutically effective amount of a mitogen-activated protein kinase (MAPK) inhibitor having the structure of Compound (I): (Compound I), or a pharmaceutically acceptable salt thereof.

The present invention relates to a novel compound and a pharmaceutical composition comprising the same as an active ingredient. The novel compound, which is obtained by means of carrying out chemical modification in a mother structure showing excellent AMP-activated protein kinase (AMPK) activation efficacy and in silico binding capacity, enables effective prevention or treatment of degenerative neurological disorders by means of effectively inducing AMP-activated protein kinase enzyme activation.

Compositions and methods for the treatment of retinal degeneration are provided. In one aspect, provided herein is adeno-associated virus (AAV) vector comprising an AAV capsid having encapsidated therein a vector genome comprising AAV inverted terminal repeat (ITR) sequences, a human protein kinase B (AKT) coding sequence, and expression control sequences that direct expression of AKT in a host cell.

The present application relates to plant complexes exhibiting a variety of synergistic antioxidant activities useful in food, dietary supplements, cosmetics and pharmaceutical formulations. Compositions comprising apple, grape, green tea, and olive extracts are presented herein. In the synergistic formulation, the apple, grape, green tea and olive extracts are used in an amount that provides antioxidant activity or protein kinase modulating activity that is greater than that provided by an equivalent amount of any one of the extracts or the sum of the extracts. Further presented are methods of modulating oxidative stress, disease-related protein kinase activity and enhancing the therapeutic effect of the primary therapeutic agent. Also presented are methods of preparing activity enhancing compositions for modulating oxidative stress, disease-related protein kinase activity and enhancing the therapeutic effect of primary therapeutic agents.

The invention relates to compounds which inhibit Cyclin-Dependent Kinases such as CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2) and CDK4 (Cyclin-Dependent Kinase 4 or Cell Division protein Kinase 4), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2 and / or CDK4.

The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.

The invention belongs to the field of biological medicines, and discloses an (R)-3-(1-([1, 1 '-biphenyl]-2-yl) ethyoxyl) pyridine-2-amine derivative as well as a synthesis method and application thereof. A compound with a structure as shown in a general formula I of the derivative or pharmaceutically acceptable salt, hydrate, solvate, polymorphic substance, tautomer, stereoisomer, isotope derivative or prodrug thereof has higher ROS1 or ALK protein kinase inhibitory activity; the compound has high anti-proliferative activity on human non-small cell lung cancer and solid tumors such as brain metastatic tumors, glioblastoma and breast cancer, and can be used for preparing drugs for treatment and / or prevention and / or delay and / or adjuvant treatment and / or treatment of tyrosine protein kinase, especially diseases mediated by ROS1 and ALK kinase and mutant kinase thereof.

The present application relates to a kind of polymorphs of FGFR4 protein kinase inhibitor and its preparation method.N-(2-(4-cyclopropylpiperazine-1-yl)-5-(4-(2,6-dichloro-3,5-dimethoxyphenyl)imidazo [1,2-a][1,6] naphthyridin-8-yl)-4-methoxyphenyl) acrylamide is a kind of FGFR4 protein kinase inhibitor, it can high selectivity inhibit FGFR4 tyrosine kinase, and the inhibitory effect of FGFR1-3 is weak, so it can safely, effectively treat the liver cancer patient of FGFR4 high expression.

The application discloses a protein kinase gene positively regulating drought resistance of oats AVESA.00022b.r1.6C0001455 and application thereof, and belongs to the technical field of plant genetic engineering. AVESA.00022b.r1.6C0001455 The CDS sequence of the gene is shown as SEQ ID NO. 1, and the amino acid sequence is shown as SEQ ID NO. 2. Expression mode analysis shows that the gene is significantly induced and up-regulated under drought stress; virus-induced gene silencing verification shows that silencing the gene can significantly reduce the drought resistance of the oats; overexpression verification shows that overexpression of the gene can significantly enhance the drought resistance of the oats, and the performance is that wilting is delayed, the water loss rate is reduced, and the survival rate is improved. The application first proves that the gene is a key positive regulation factor of drought resistance in the oats, and can be used for cultivating drought-resistant transgenic plants and as a drought-resistant molecular marker for assisted breeding, and has important application value in genetic improvement of crop drought resistance.

The invention discloses an application of protein kinase CPK28 (GenBank: AT5G66210) in endowing or enhancing aluminum resistance of plants, and the CPK28 is overexpressed in the plants, so that a zinc finger transcription factor STOP1 can be phosphorylated, and the protein accumulation of the STOP1 is improved, thereby enabling the plants to generate or enhance the aluminum toxicity resistance. The invention provides a theoretical basis for culturing aluminum toxicity resistant crops.

Provided is a novel serine-arginine protein kinase (SRPK) inhibitor. More specifically, provided is the novel SRPK inhibitor C-DBS. The novel SRPK inhibitor C-DBS is a covalent protein-protein interaction inhibitor against SRPK and is used in methods oftreating cancers or viral infections.

The disclosure relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a dystrophy myotonic protein kinase (DMPK) gene, as well as methods of inhibiting expression of a DMPK gene and methods of treating subjects having a DMPK-associated disease or disorder, e.g., myotonic dystrophy (DM), using such dsRNA agents and compositions.

The application belongs to the field of plant genetic engineering, and discloses a key gene for positively regulating salt stress and oxidation stress tolerance of rice OsHPCA1 . The gene (accession number: Os05g40770) encodes a receptor protein specifically sensing hydrogen peroxide, which is classified into the leucine repeat receptor-like kinase (LRR-RLKs) family, which is the largest subfamily in the receptor-like kinase (RLKs) family. OsHPCA1 In response to salt and oxidation stress signals, the rice salt and oxidation stress tolerance is positively regulated. OsHPCA1 The overexpression rice strain shows strong salt tolerance; and OsHPCA1 the knockout strain oshpca1 is more sensitive to salt stress. OsHPCA1 The leucine repeat receptor protein kinase OsHPCA1 encoded by the gene can positively regulate the activity of catalase C (CatC) in the rice body, enhance the H2O2 clearance efficiency under salt stress, and thus improve the salt tolerance of the rice. When OsHPCA1 overexpressed, the activity of CatC in the overexpression strain OsHPCA1 is significantly increased, the H2O2 clearance capacity is enhanced, and the salt tolerance and oxidation stress tolerance of the rice are improved.

The present invention provides compounds that inhibit rho-associated protein kinase (ROCK) for therapeutic uses as further described herein.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

A novel compound that is a protein degradation-inducing part of the proto-oncogene tyrosine protein kinase receptor (RET), wherein the RET may be wild-type RET or a mutant form of RET.

Provided herein are compounds and compositions thereof that reduce WEE1 kinase protein levels. In some embodiments, the compounds and compositions are provided for treatment WEE1 associated diseases such as cancer.

The application relates to the field of molecular biology technology, and particularly relates to application of a pineapple calcium-dependent protein kinase gene in prevention and treatment of pineapple water core disease; the pineapple calcium-dependent protein kinase gene comprises AcCPK4, AcCPK8 and / or AcCPK15 genes, the CDS sequence of which is shown as SEQ ID NO. 1-3; the gene is transiently expressed in pineapple fruits, can significantly inhibit the pineapple water core disease, and provides important theoretical support for analysis of a pineapple water core disease mechanism and cultivation of high-quality pineapple varieties resistant to the water core disease.

The invention relates to the technical field of molecular biology, in particular to application of a pineapple calcium-dependent protein kinase gene in prevention and treatment of a pineapple hydroheart disease. The pineapple calcium dependent protein kinase gene comprises an AcCPK4 gene, an AcCPK8 gene and / or an AcCPK15 gene, and the CDS sequence of the AcCPK4 gene, the AcCPK8 gene and / or the AcCPK15 gene is as shown in SEQ ID NO.1-3; the gene is transiently expressed in a pineapple fruit, the pineapple hydroheart disease can be remarkably inhibited, and an important theoretical support is provided for analysis of a pineapple hydroheart disease mechanism and cultivation of a high-quality hydroheart disease-resistant pineapple variety.